Outlook Therapeutics Narrows Q2 Loss to $4.5M, Swiss LYTENAVA Deal
Outlook Therapeutics reported a Q2 FY2026 net loss of $4.5 million versus $46.4 million a year ago, driven by cost restructuring and lower European unit sales. The company expanded LYTENAVA distribution through a Swiss agreement targeting 2027 launch and awaits an FDA decision on ONS-5010 this month.
1. Q2 FY2026 Financial Performance
Outlook Therapeutics reported a net loss of $4.5 million, or $0.05 per share, in the quarter ended March 31, 2026, compared with a $46.4 million loss a year ago. Adjusted net loss was $14.1 million, reflecting gains from warrant and debt fair value changes, while European unit sales dipped about 10% quarter-over-quarter but showed early signs of recovery.
2. European Commercial Expansion
The company entered a distribution agreement with Mediconsult AG to launch LYTENAVA in Switzerland, targeting a 2027 introduction subject to Marketing Authorization. Plans are in place to expand into the Netherlands and Ireland later in 2026, alongside a real-world evidence study in Germany to support market access and reimbursement.
3. U.S. Regulatory Progress
Outlook Therapeutics completed a formal dispute resolution meeting with the FDA on its ophthalmic bevacizumab candidate ONS-5010 and expects the agency’s decision in May 2026. The submission package includes clinical, pharmacodynamic and safety data from the NORSE TWO and NORSE EIGHT studies, underpinning its bid for U.S. approval.
4. Capital Structure and Liquidity
In March and April 2026, the company secured approximately $8.2 million in net proceeds through public and registered direct offerings, and restructured promissory notes to extend maturities. As of March 31, 2026, cash and equivalents stood at $7.7 million, excluding proceeds from the April offering.